These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 21694463)
1. Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. Lim NK; Villemagne VL; Soon CP; Laughton KM; Rowe CC; McLean CA; Masters CL; Evin G; Li QX J Alzheimers Dis; 2011; 26(4):779-86. PubMed ID: 21694463 [TBL] [Abstract][Full Text] [Related]
2. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Lorenzl S; Buerger K; Hampel H; Beal MF Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439 [TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Horstmann S; Budig L; Gardner H; Koziol J; Deuschle M; Schilling C; Wagner S Int Psychogeriatr; 2010 Sep; 22(6):966-72. PubMed ID: 20561382 [TBL] [Abstract][Full Text] [Related]
5. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD; J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723 [TBL] [Abstract][Full Text] [Related]
6. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. Hanzel CE; Iulita MF; Eyjolfsdottir H; Hjorth E; Schultzberg M; Eriksdotter M; Cuello AC J Alzheimers Dis; 2014; 40(3):667-78. PubMed ID: 24531161 [TBL] [Abstract][Full Text] [Related]
7. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment. Fei M; Jianghua W; Rujuan M; Wei Z; Qian W J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911 [TBL] [Abstract][Full Text] [Related]
8. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636 [TBL] [Abstract][Full Text] [Related]
11. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. Mroczko B; Groblewska M; Zboch M; Kulczyńska A; Koper OM; Szmitkowski M; Kornhuber J; Lewczuk P J Alzheimers Dis; 2014; 40(2):351-7. PubMed ID: 24448781 [TBL] [Abstract][Full Text] [Related]
12. MMP-2, -3 and -9 levels and activity are not related to Abeta load in the frontal cortex in Alzheimer's disease. Baig S; Kehoe PG; Love S Neuropathol Appl Neurobiol; 2008 Apr; 34(2):205-15. PubMed ID: 17971072 [TBL] [Abstract][Full Text] [Related]
13. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013 [TBL] [Abstract][Full Text] [Related]
15. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Rembach A; Faux NG; Watt AD; Pertile KK; Rumble RL; Trounson BO; Fowler CJ; Roberts BR; Perez KA; Li QX; Laws SM; Taddei K; Rainey-Smith S; Robertson JS; Vandijck M; Vanderstichele H; Barnham KJ; Ellis KA; Szoeke C; Macaulay L; Rowe CC; Villemagne VL; Ames D; Martins RN; Bush AI; Masters CL; Alzheimers Dement; 2014 Jan; 10(1):53-61. PubMed ID: 23491263 [TBL] [Abstract][Full Text] [Related]
16. Increased plasma levels of lipocalin 2 in mild cognitive impairment. Choi J; Lee HW; Suk K J Neurol Sci; 2011 Jun; 305(1-2):28-33. PubMed ID: 21463871 [TBL] [Abstract][Full Text] [Related]
17. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Degerman Gunnarsson M; Lindau M; Wall A; Blennow K; Darreh-Shori T; Basu S; Nordberg A; Larsson A; Lannfelt L; Basun H; Kilander L Dement Geriatr Cogn Disord; 2010; 29(3):204-12. PubMed ID: 20332638 [TBL] [Abstract][Full Text] [Related]
18. Elevated matrix metalloproteinase-9 levels in neuronal extracellular vesicles in Alzheimer's disease. Gu D; Liu F; Meng M; Zhang L; Gordon ML; Wang Y; Cai L; Zhang N Ann Clin Transl Neurol; 2020 Sep; 7(9):1681-1691. PubMed ID: 32790155 [TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and their multiple roles in Alzheimer's disease. Wang XX; Tan MS; Yu JT; Tan L Biomed Res Int; 2014; 2014():908636. PubMed ID: 25050378 [TBL] [Abstract][Full Text] [Related]
20. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]